Replies to post #268892 on Avid Bioservices Inc (CDMO)

[geocappy1]

I thought we replaced Yervoy with AZN drug because it was free and Yervoy expensive for trial. And, the combo results were better in pre-clinical

[vinmantoo]

I suppose data does need to be analyzed


Are you new to biotech?

Do you think it takes 4 months to analyze data from a very small phase I trial, especially when the primary endpoint is toxicity? There were supposedly 16 patients in the Bavi + Ipilimumab arm vs 8 in the Ipilimumab arm vs 8 in the ipi control arm.

By the was, jq1234 is on of the best biotech posters I have run across so your comment was unwaranted.

[exwannabe]

I suppose data does need to be analyzed Are you new to biotech?

It is an open label trial with less than 20 enrolled (we do not know the actual number).

Most likely the final secondary endpoint (at 27 weeks) would have been hit at least 1/2 year ago.

How long does it take to get numbers on a small open label trial?

Yeah, a formal paper could well take a year to get published. But key numbers could be PR'd as soon as they had the math. And that they do have.

Here is something I have noticed investing in biotech. Good news comes out as soon as it can, bad news as slow as it can.

[revenue_monster]

didnt they shelve this trial. was buried in one of the quarterly reports due to a change in SOC

[jq1234]

>> Are you new to biotech?


Yes, I am new to biotech, I didn't know it would take 4 months to analyze a less than 24 patients trial with ORR/DCR as key endpoint. It doesn't sound like there is POC clinical data matching preclinical mouse model to someone who is new to biotech.

Btw, one of big pharma favorite IO combination target IDO had initial POC clinical data in combination with Yervoy in melanoma, then with anti-PD1, currently in ph3 combination with Keytruda for melanoma.